Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer

[1]  A. Ballabio,et al.  A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours , 2021, Nature Nanotechnology.

[2]  Tsonwin Hai,et al.  Stress-Inducible Gene Atf3 Dictates a Dichotomous Macrophage Activity in Chemotherapy-Enhanced Lung Colonization , 2021, International journal of molecular sciences.

[3]  Amy R. Peck,et al.  Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies. , 2021, The Journal of clinical investigation.

[4]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[5]  C. Reis e Sousa,et al.  Dendritic Cells Revisited. , 2021, Annual review of immunology.

[6]  Chuan-Yuan Li,et al.  PCSK9 inhibition potentiates cancer immune checkpoint therapy , 2020, Nature.

[7]  A. Mantovani,et al.  Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade , 2020, Immunity.

[8]  Andrew M Haidle,et al.  An orally available non-nucleotide STING agonist with antitumor activity , 2020, Science.

[9]  H. M. Petrassi,et al.  Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic , 2020, Science.

[10]  Emil Polyak,et al.  Homeostasis , 2019, The Life of Training.

[11]  D. Fremont,et al.  Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion , 2020, Proceedings of the National Academy of Sciences.

[12]  P. Saftig,et al.  Cholesterol Handling in Lysosomes and Beyond. , 2020, Trends in cell biology.

[13]  J. Debnath,et al.  Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I , 2020, Nature.

[14]  M. Hung,et al.  ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. , 2020, Cancer cell.

[15]  S. Sauer,et al.  Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells , 2020, Cancer Immunology, Immunotherapy.

[16]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[17]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[18]  B. Reizis,et al.  Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells , 2019, The Journal of experimental medicine.

[19]  Abhishek S. Rao,et al.  Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer , 2019, Science Translational Medicine.

[20]  H. Rui,et al.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. , 2019, Cancer cell.

[21]  C. Reis e Sousa,et al.  The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity , 2018, Trends in cancer.

[22]  A. Vincent-Salomon,et al.  Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific , 2018, Nature Immunology.

[23]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[24]  J. Blander.  Regulation of the Cell Biology of Antigen Cross-Presentation. , 2018, Annual review of immunology.

[25]  C. Jakubzick,et al.  Isolation and Characterization of Mononuclear Phagocytes in the Mouse Lung and Lymph Nodes. , 2018, Methods in molecular biology.

[26]  T. P. Neufeld,et al.  Membrane Trafficking in Autophagy. , 2018, International review of cell and molecular biology.

[27]  J. Klein-Seetharaman,et al.  Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer , 2017, Nature Communications.

[28]  R. Amaravadi,et al.  Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors , 2017, International journal of molecular sciences.

[29]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[30]  D. Gabrilovich,et al.  Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.

[31]  Qinghua Zhou,et al.  Activating transcription factor 3 promotes malignance of lung cancer cells in vitro , 2017, Thoracic cancer.

[32]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[33]  Kevin A. Robertson,et al.  Interferon Control of the Sterol Metabolic Network: Bidirectional Molecular Circuitry-Mediating Host Protection , 2016, Front. Immunol..

[34]  K. Murphy,et al.  Functions of Murine Dendritic Cells. , 2016, Immunity.

[35]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[36]  Abhishek S. Rao,et al.  Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. , 2016, Cancer cell.

[37]  K. Pienta,et al.  Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation , 2016, Journal of visualized experiments : JoVE.

[38]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[39]  K. Gevaert,et al.  Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens. , 2015, Immunity.

[40]  M. Hendzel,et al.  Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells , 2015, MethodsX.

[41]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[42]  R. Bartenschlager,et al.  Interferon‐inducible cholesterol‐25‐hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation , 2015, Hepatology.

[43]  L. Zitvogel,et al.  Autocrine signaling of type 1 interferons in successful anticancer chemotherapy , 2015, Oncoimmunology.

[44]  Juan R. Cubillos-Ruiz,et al.  ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis , 2015, Cell.

[45]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[46]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[47]  S. Singhal,et al.  An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells , 2015, Journal of leukocyte biology.

[48]  A. Ballabio,et al.  Lysosome: regulator of lipid degradation pathways , 2014, Trends in cell biology.

[49]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[50]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[51]  J. Cyster,et al.  25-Hydroxycholesterols in innate and adaptive immunity , 2014, Nature Reviews Immunology.

[52]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[53]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[54]  Florent Ginhoux,et al.  Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny , 2014, Nature Reviews Immunology.

[55]  L. Zitvogel,et al.  Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer , 2014, Oncogene.

[56]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[57]  Michael C. Ostrowski,et al.  Transcription factor ATF3 links host adaptive response to breast cancer metastasis. , 2013, The Journal of clinical investigation.

[58]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[59]  Qinghua Zhou,et al.  Association between the ATF3 gene and non‐small cell lung cancer , 2012, Thoracic cancer.

[60]  R. Moritz,et al.  ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol–induced lipid body formation , 2012, The Journal of experimental medicine.

[61]  P. Murray.  Faculty Opinions recommendation of CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011 .

[62]  William A Weiss,et al.  Principles and Current Strategies for Targeting Autophagy for Cancer Treatment , 2011, Clinical Cancer Research.

[63]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[64]  Kiwon Park,et al.  Cholesterol 25‐hydroxylase production by dendritic cells and macrophages is regulated by type I interferons , 2010, Journal of leukocyte biology.

[65]  M. Fishman,et al.  Lipid accumulation and dendritic cell dysfunction in cancer , 2007, Nature Medicine.

[66]  P. Guermonprez,et al.  Measuring pH, ROS production, maturation, and degradation in dendritic cell phagosomes using cytofluorometry-based assays. , 2010, Methods in molecular biology.

[67]  N. Hacohen,et al.  The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. , 2009, Immunity.

[68]  L. Zitvogel,et al.  The immunogenicity of tumor cell death , 2009, Current opinion in oncology.

[69]  M. Ahmadi,et al.  Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. , 2008, Cancer research.

[70]  D. Accapezzato,et al.  Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo , 2005, The Journal of experimental medicine.

[71]  Henry C. Chang,et al.  Differential Lysosomal Proteolysis in Antigen-Presenting Cells Determines Antigen Fate , 2005, Science.

[72]  J. Frelinger,et al.  Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.

[73]  A. Nègre-Salvayre,et al.  Oxidized low-density lipoprotein-induced apoptosis. , 2002, Biochimica et biophysica acta.

[74]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.